"In the first quarter, trends remained elevated ... Brian Evanko, Cigna's chief operating officer, noted that Cigna had increased stop-loss prices for 2025 because of the surge in claims.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

On Wednesday, Bernstein analysts increased their price target for Cigna Corporation (NYSE: CI) shares from $323.00 to $373.00, while maintaining a Market Perform rating.The healthcare giant, with ...

Ladies and gentlemen, thank you for standing by for the Cigna Group's First Quarter 2025 ... we are working tirelessly to lower prescription drug prices for more than 100 million Americans and ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Peter Schiff criticized Scott Bessent for downplaying Trump's tax cuts in the recent Moody's downgrade, instead blaming Biden ...

Cordani emphasized the company’s dual growth platforms, Evernorth (health services) and Cigna Healthcare ... to execute on pricing adjustments and manage specialty drug costs.

HQH trades at an 8% discount to NAV, offering an attractive entry point compared to peers, despite recent price declines.

Health insurance company Cigna (NYSE:CI ... The company cited persistent medical cost trends, evolving drug pricing dynamics, and regulatory changes (e.g., state-level PBM legislation) as key ...

Cigna Group’s drug benefit unit is offering a new way for health plans to cover expensive weight-loss drugs that it says will ...

Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come ...

U.S. prices for new drugs more than doubled last year compared to 2021, as companies developed more therapies for rare ...